Literature DB >> 26742632

Age-related macular degeneration: Complement in action.

Menno van Lookeren Campagne1, Erich C Strauss2, Brian L Yaspan3.   

Abstract

The complement system plays a key role in host-defense against common pathogens but must be tightly controlled to avoid inflammation and tissue damage. Polymorphisms in genes encoding two important negative regulators of the alternative complement pathway, complement factor H (CFH) and complement factor I (CFI), are associated with the risk for Age-Related Macular Degeneration (AMD), a leading cause of vision impairment in the ageing population. In this review, we will discuss the genetic basis of AMD and the potential impact of complement de-regulation on disease pathogenesis. Finally, we will highlight recent therapeutic approaches aimed at controlling complement activation in patients with AMD.
Copyright © 2015 The Authors. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Keywords:  Age-related macular degeneration; Complement; Genetics

Mesh：

Substances：

Year:  2015        PMID： 26742632     DOI： 10.1016/j.imbio.2015.11.007

Source DB:  PubMed          Journal:  Immunobiology        ISSN： 0171-2985            Impact factor:   3.144


  32 in total

Review 1.  The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Authors:  Joshua M Thurman; Ashley Frazer-Abel; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2017-10-17       Impact factor: 10.995

Review 2.  Clinical promise of next-generation complement therapeutics.

Authors:  Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Rev Drug Discov       Date:  2019-07-19       Impact factor: 84.694

3.  Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization.

Authors:  Nathaniel Parsons; Balasubramaniam Annamalai; Elisabeth Obert; Gloriane Schnabolk; Stephen Tomlinson; Bärbel Rohrer
Journal:  Mol Immunol       Date:  2019-02-12       Impact factor: 4.407

Review 4.  Novel mechanisms and functions of complement.

Authors:  George Hajishengallis; Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; John D Lambris
Journal:  Nat Immunol       Date:  2017-11-16       Impact factor: 25.606

Review 5.  New milestones ahead in complement-targeted therapy.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-06-16       Impact factor: 11.130

6.  A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system.

Authors:  Henrik Pedersen; Rasmus K Jensen; Annette G Hansen; Trine A F Gadeberg; Steffen Thiel; Nick S Laursen; Gregers R Andersen
Journal:  J Biol Chem       Date:  2020-05-06       Impact factor: 5.157

Review 7.  Can innate and autoimmune reactivity forecast early and advance stages of age-related macular degeneration?

Authors:  Grazyna Adamus
Journal:  Autoimmun Rev       Date:  2017-01-28       Impact factor: 9.754

8.  Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.

Authors:  Sarah Hughes; Justin Gumas; Rebecca Lee; Merita Rumano; Nadja Berger; Avneesh Kumar Gautam; Georgia Sfyroera; Anna Lorena Chan; Gopalan Gnanaguru; Kip M Connor; Benjamin J Kim; Joshua L Dunaief; Daniel Ricklin; George Hajishengallis; Despina Yancopoulou; Edimara S Reis; Dimitrios C Mastellos; John D Lambris
Journal:  Clin Immunol       Date:  2020-03-27       Impact factor: 3.969

Review 9.  A Revised Hemodynamic Theory of Age-Related Macular Degeneration.

Authors:  Bradley D Gelfand; Jayakrishna Ambati
Journal:  Trends Mol Med       Date:  2016-07-13       Impact factor: 11.951

Review 10.  New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.

Authors:  V Michael Holers; Stephen Tomlinson; Liudmila Kulik; Carl Atkinson; Bärbel Rohrer; Nirmal Banda; Joshua M Thurman
Journal:  Semin Immunol       Date:  2016-06-06       Impact factor: 11.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.